News

Wall Street Trims Ratings for Novo Nordisk Stock, as Ozempic’s Competition Grows
Guggenheim’s Seamus Fernandez cut his rating on Novo Nordisk stock to Hold from Buy on Thursday, as did Evan David Seigerman ...
Futurism on MSN6h
Novo Nordisk Is Getting Absolutely Destroyed
Shares of Novo Nordisk, the Danish pharmaceutical company behind the groundbreaking GLP-1 weight-loss drugs Ozempic and ...
Eli Lilly Shares Up 13% After Weight Loss Pill Appears As Effective As Ozempic And Mounjaro In Trials
Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...
Lilly weight-loss pill works as well as Ozempic, shares surge
Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of ...
Daily Pill May Work as Well as Ozempic for Weight Loss and Blood Sugar
Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...
Novo Nordisk: A Price Too Low To Ignore
Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.
BenefitsPRO8h
Eli Lilly’s new GLP-1 weight loss drug, in pill form, would be more affordable than Ozempic
Orforglipron, which could become the first GLP-1 pill — a much more convenient option — is a step closer to hitting the ...
Novo Nordisk May Lag Behind Eli Lilly In Cardiometabolic Race, Analyst Downgrades Stock
The analyst highlights that Lilly’s drugs, Mounjaro and Zepbound, will likely keep gaining U.S. market share from Novo ...